Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer

BACKGROUND: The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrichiello, Gianluca, Perrone, Alessandra, Napolitano, Stefania, Martini, Giulia, De Falco, Vincenzo, Incoronato, Pasquale, Laterza, Maria Maddalena, Facchini, Gaetano, Famiglietti, Vincenzo, Nacca, Valeria, Paragliola, Fernando, Napolitano, Rossella, Suarato, Gabriella, Nicastro, Antonella, Martinelli, Erika, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684226/
https://www.ncbi.nlm.nih.gov/pubmed/36239883
http://dx.doi.org/10.1007/s11523-022-00916-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684226/
https://www.ncbi.nlm.nih.gov/pubmed/36239883
http://dx.doi.org/10.1007/s11523-022-00916-8

Ejemplares similares